FDA's Makary calls for tying fast-review vouchers to lower US prices, without specifics

Andrew Dunn

Senior Biopharma Correspondent

FDA Commissioner Marty Makary is calling for a seemingly unprecedented idea of dangling the promise of speedy reviews for experimental medicines in exchange for drugmakers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

FDA's Makary calls for tying fast-review vouchers to lower US prices, without specifics

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Sally Susman waves goodbye to Pfizer; Xaira's new president and COO

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

FDA hands Capricor a CRL for its Duchenne cell therapy

Century Therapeutics lays off half of its staff, CFO departs as it narrows priorities

Karyopharm cuts 20% of staff as it looks at 'strategic alternatives' or raising cash

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases

FDA's Makary calls for ty­ing fast-re­view vouch­ers to low­er US prices, with­out specifics

Andrew Dunn

Senior Biopharma Correspondent

Sign up to read this article for free.

Sal­ly Sus­man waves good­bye to Pfiz­er; Xaira's new pres­i­dent and COO

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

FDA hands Capri­cor a CRL for its Duchenne cell ther­a­py

Cen­tu­ry Ther­a­peu­tics lays off half of its staff, CFO de­parts as it nar­rows pri­or­i­ties

Karyopharm cuts 20% of staff as it looks at 's­trate­gic al­ter­na­tives' or rais­ing cash

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

FDA's Makary calls for tying fast-review vouchers to lower US prices, without specifics

Sally Susman waves goodbye to Pfizer; Xaira's new president and COO

Biotech’s Q2 numbers paint a picture of the good, the bad and the ugly

FDA hands Capricor a CRL for its Duchenne cell therapy

Century Therapeutics lays off half of its staff, CFO departs as it narrows priorities

Karyopharm cuts 20% of staff as it looks at 'strategic alternatives' or raising cash

Uncovering the Potential of Targeting the CD38 Pathway for Immune-Mediated Diseases